PRVB: Q3 2022 Update & Outlook
Full rundown on Provention Bio (PRVB) as the Q3 2022 quarterly call and November 17 PDUFA dates approach…
Full rundown on Provention Bio (PRVB) as the Q3 2022 quarterly call and November 17 PDUFA dates approach…
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
Key takeaways from the latest quarterly report from Atomera Inc. (ATOM), including the possible identity of the latest “major” foundry customer…
Low float stocks are prone to major moves on nominal volume. Unfortunately in both directions. Here’s what’s going on with IMNM…
In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data
Per your feedback, here’s my quick take on Atomera’s fourth quarter report…
Resonant Inc. (RESN) announced it’s being acquired for $4.50 per share by long-term strategic partner, Murata
Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…
Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.